Koninklijke Philips (PHG) said Tuesday that it has launched an international clinical investigation evaluating its ultra-low X-ray dose technology in coronary procedures.

The multicenter, randomized study will enroll 824 coronary artery disease patients in six hospitals in Spain, Czech Republic, and the US, with the aim of showing that the new technology can reduce overall patient radiation exposure without affecting coronary procedures, according to the company.

The trial evaluates radiation exposure, image quality, and procedural performance between Philips' technology and existing ClarityIQ technology, the company said.